WCFA
VRTX icon

Walkner Condon Financial Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Walkner Condon Financial Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$285K Sell
573
-5
-0.9% -$2.22K 0.03% 273
2026
Q1 		$258K Buy
+578
New +$270K 0.03% 270

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Walkner Condon Financial Advisors's VRTX Position: Q2 2026 in Review

Walkner Condon Financial Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 0.87% in Q2 2026, selling an estimated $2.22K and leaving 573 shares worth $285K. The position accounts for 0.03% of the portfolio, ranked #273.

Walkner Condon Financial Advisors first reported a position in VRTX in Q1 2026 and has held it in 2 quarters since. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Walkner Condon Financial Advisors held 573 shares of Vertex Pharmaceuticals worth $285K as of Q2 2026.
  • Walkner Condon Financial Advisors sold 5 Vertex Pharmaceuticals shares in Q2 2026, an estimated $2.22K.
  • Vertex Pharmaceuticals made up 0.03% of Walkner Condon Financial Advisors's portfolio in Q2 2026, its #273 holding.
  • Walkner Condon Financial Advisors first reported a position in Vertex Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Walkner Condon Financial Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.